GlassScriptPhysician profile
Steven J Wilson
NPI 1831167006
$10,032.33
in general payments reported to CMS, 2019-2025
13 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,889 · 2020: $266 · 2021: $401 · 2022: $2,573 · 2023: $1,530 · 2024: $1,324 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Travel and Lodging: $1,688 · Education: $34.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.50 |
| Travel and Lodging | $1,688.34 |
| Education | $34.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,612.94 | 2019-2025 | Mako, Pangea, Iconix |
| Arthrex, INC. | $4,127.98 | 2019-2023 | Distal Extremities Implants Trauma |
| Pylant Medical | $419.32 | 2019-2025 | |
| Pacira Therapeutics, INC. | $182.75 | 2019-2021 | |
| Depuy Synthes Sales INC. | $161.95 | 2019-2025 | |
| Amgen INC. | $124.99 | 2024 | Krystexxa |
| Pacira Pharmaceuticals Incorporated | $106.66 | 2019-2022 | |
| Baudax Bio INC. | $91.71 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $77.27 | 2024-2025 | |
| Kci USA, INC. | $50.29 | 2019 | |
| Boston Scientific Corporation | $38.44 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $25.98 | 2025 | Euflexxa |
| Avanos Medical | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.